ACTRN12608000362392已完成不适用
An international randomised controlled trial to establish the effects of early intensive blood pressure lowering in patients with intracerebral haemorrhage
The George Institute for International Health0 个研究点目标入组 2,800 人开始时间: 2008年7月25日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 2,800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 ot stated（—）
- 性别
- All
入选标准
- •Patients with computerised tomography (CT)-confirmed spontaneous Intracerebral Haemorrhage (ICH) and elevated systolic blood pressure (>150mmHg and <220mmHg), capacity to commence randomly assigned treatment within 6 hours of onset of ICH.
排除标准
- •Clear indication or contraindication to intensive BP lowering. Evidence ICH secondary to a structural abnormality, or use of thrombolytic agent, an ischaemic stroke within 30 days, a score of 3-5 on the Glasgow Coma Scale (indicating deep coma), significant pre-stroke disability or medical illness, planned early neurological intervention and participation in another clinical trial.
研究者
相似试验
已完成
不适用
The second intensive blood pressure reduction in acute cerebral haemorrhage trialIntracerebral haemorrhageCirculatory SystemISRCTN73916115ational Health and Medical Research Council (NHMRC) (Australia)2,839
已完成
3 期
Enhanced control of hypertension and thrombolysis stroke studyIschaemic strokeStroke - IschaemicCardiovascular - HypertensionHypertensionACTRN12611000236998The George Institute for Global Health4,587
已完成
3 期
The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial.CTRI/2009/091/000052The National Health and Medical Research Council NHMRC of Australia2,839
已完成
不适用
A multicentre international randomised trial to evaluate percutaneous endoscopic gastrostomy (PEG) and nasogastric (NG) tube feeding in patients admitted to hospital with a recent strokeCirculatory SystemStrokeISRCTN65375365Department of Health (UK)4,023
已完成
不适用
An international study designed to answer reliably whether, for women who have hormone sensitive early breast cancer (the most common type of breast cancer), 10 years of adjuvant tamoxifen (a hormone treatment) confers more benefit than just 5 years in terms of reducing the risk of relapse and improving overall, long-term survival: Adjuvant Tamoxifen - Longer Against Shorter (ATLAS)Operable, oestrogen receptor positive breast cancer already trated with ~5 years of adjuvant tamoxifenMalignant neoplasm of breastCancerISRCTN19652633niversity of Oxford (UK)15,262